UPCC 09220: Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Esophagogastric Adenocarcinoma

Site Image

Study Overview

The purpose of this study is to test the effects of the research study drug Telomelysin (OBP-301) in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. Eligible subjects are those with advanced or metastatic cancer of the stomach or junction between the stomach and esophagus.

  • Study Identifier: 843696

Recruitment Status

Enrolling By Invitation

For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com